Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225139418> ?p ?o ?g. }
- W4225139418 endingPage "1634.e4" @default.
- W4225139418 startingPage "1622" @default.
- W4225139418 abstract "BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with predominant antibody deficiency (PAD) is associated with high morbidity, yet data regarding the response to SARS-CoV-2 immunization in PAD patients, including additional dose vaccine, are limited.ObjectiveTo characterize antibody response to SARS-CoV-2 vaccine in PAD patients and define correlates of vaccine response.MethodsWe assessed the levels and function of anti-SARS-CoV-2 antibodies in 62 PAD patients compared with matched healthy controls at baseline, at 4 to 6 weeks after the initial series of immunization (a single dose of Ad26.COV2.S [Janssen] or two doses of BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]), and at 4 to 6 weeks after an additional dose immunization, if received.ResultsAfter the initial series of SARS-CoV-2 vaccination, PAD patients had lower mean anti-spike antibody levels compared with matched healthy controls (140.1 vs 547.3 U/mL; P = .02). Patients with secondary PAD (eg, B-cell depletion therapy was used) and those with severe primary PAD (eg, common variable immunodeficiency with autoinflammatory complications) had the lowest mean anti-spike antibody levels. Immune correlates of a low anti-spike antibody response included low CD4+ T helper cells, low CD19+ total B cells, and low class-switched memory (CD27+IgD/M–) B cells. In addition, a low (<100 U/mL) anti-spike antibody response was associated with prior exposure to B-cell depletion therapy, both at any time in the past (odds ratio = 5.5; confidence interval, 1.5-20.4; P = .01) and proximal to vaccination (odds ratio = 36.4; confidence interval, 1.7-791.9; P = .02). Additional dose immunization with an mRNA vaccine in a subset of 31 PAD patients increased mean anti-spike antibody levels (76.3 U/mL before to 1065 U/mL after the additional dose; P < .0001).ConclusionsPatients with secondary and severe primary PAD, characterized by low T helper cells, low B cells, and/or low class-switched memory B cells, were at risk for low antibody response to SARS-CoV-2 immunization, which improved after an additional dose vaccination in most patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with predominant antibody deficiency (PAD) is associated with high morbidity, yet data regarding the response to SARS-CoV-2 immunization in PAD patients, including additional dose vaccine, are limited. To characterize antibody response to SARS-CoV-2 vaccine in PAD patients and define correlates of vaccine response. We assessed the levels and function of anti-SARS-CoV-2 antibodies in 62 PAD patients compared with matched healthy controls at baseline, at 4 to 6 weeks after the initial series of immunization (a single dose of Ad26.COV2.S [Janssen] or two doses of BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]), and at 4 to 6 weeks after an additional dose immunization, if received. After the initial series of SARS-CoV-2 vaccination, PAD patients had lower mean anti-spike antibody levels compared with matched healthy controls (140.1 vs 547.3 U/mL; P = .02). Patients with secondary PAD (eg, B-cell depletion therapy was used) and those with severe primary PAD (eg, common variable immunodeficiency with autoinflammatory complications) had the lowest mean anti-spike antibody levels. Immune correlates of a low anti-spike antibody response included low CD4+ T helper cells, low CD19+ total B cells, and low class-switched memory (CD27+IgD/M–) B cells. In addition, a low (<100 U/mL) anti-spike antibody response was associated with prior exposure to B-cell depletion therapy, both at any time in the past (odds ratio = 5.5; confidence interval, 1.5-20.4; P = .01) and proximal to vaccination (odds ratio = 36.4; confidence interval, 1.7-791.9; P = .02). Additional dose immunization with an mRNA vaccine in a subset of 31 PAD patients increased mean anti-spike antibody levels (76.3 U/mL before to 1065 U/mL after the additional dose; P < .0001). Patients with secondary and severe primary PAD, characterized by low T helper cells, low B cells, and/or low class-switched memory B cells, were at risk for low antibody response to SARS-CoV-2 immunization, which improved after an additional dose vaccination in most patients." @default.
- W4225139418 created "2022-05-01" @default.
- W4225139418 creator A5002180213 @default.
- W4225139418 creator A5010332288 @default.
- W4225139418 creator A5012891156 @default.
- W4225139418 creator A5013097108 @default.
- W4225139418 creator A5014757042 @default.
- W4225139418 creator A5017423714 @default.
- W4225139418 creator A5036760276 @default.
- W4225139418 creator A5043793593 @default.
- W4225139418 creator A5056275493 @default.
- W4225139418 creator A5059386925 @default.
- W4225139418 creator A5059906345 @default.
- W4225139418 creator A5061316293 @default.
- W4225139418 creator A5061978120 @default.
- W4225139418 creator A5064814823 @default.
- W4225139418 creator A5066059486 @default.
- W4225139418 creator A5069533019 @default.
- W4225139418 creator A5069840184 @default.
- W4225139418 creator A5074596928 @default.
- W4225139418 creator A5079708396 @default.
- W4225139418 creator A5079990486 @default.
- W4225139418 creator A5083608773 @default.
- W4225139418 creator A5084283817 @default.
- W4225139418 creator A5085694830 @default.
- W4225139418 date "2022-06-01" @default.
- W4225139418 modified "2023-10-16" @default.
- W4225139418 title "Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency" @default.
- W4225139418 cites W2134678353 @default.
- W4225139418 cites W2137140783 @default.
- W4225139418 cites W2235970093 @default.
- W4225139418 cites W2292472819 @default.
- W4225139418 cites W2783068730 @default.
- W4225139418 cites W3005664566 @default.
- W4225139418 cites W3018910405 @default.
- W4225139418 cites W3087862874 @default.
- W4225139418 cites W3088841124 @default.
- W4225139418 cites W3097263615 @default.
- W4225139418 cites W3109136263 @default.
- W4225139418 cites W3109331896 @default.
- W4225139418 cites W3111255098 @default.
- W4225139418 cites W3119345685 @default.
- W4225139418 cites W3120327534 @default.
- W4225139418 cites W3130382644 @default.
- W4225139418 cites W3132243507 @default.
- W4225139418 cites W3133532742 @default.
- W4225139418 cites W3134111715 @default.
- W4225139418 cites W3137469790 @default.
- W4225139418 cites W3163107220 @default.
- W4225139418 cites W3164747805 @default.
- W4225139418 cites W3168349393 @default.
- W4225139418 cites W3171855736 @default.
- W4225139418 cites W3172793935 @default.
- W4225139418 cites W3177433651 @default.
- W4225139418 cites W3187336349 @default.
- W4225139418 cites W3197504359 @default.
- W4225139418 cites W3198728287 @default.
- W4225139418 cites W3206020366 @default.
- W4225139418 cites W4200498553 @default.
- W4225139418 cites W4205483821 @default.
- W4225139418 cites W4226162867 @default.
- W4225139418 doi "https://doi.org/10.1016/j.jaip.2022.03.017" @default.
- W4225139418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35381395" @default.
- W4225139418 hasPublicationYear "2022" @default.
- W4225139418 type Work @default.
- W4225139418 citedByCount "11" @default.
- W4225139418 countsByYear W42251394182022 @default.
- W4225139418 countsByYear W42251394182023 @default.
- W4225139418 crossrefType "journal-article" @default.
- W4225139418 hasAuthorship W4225139418A5002180213 @default.
- W4225139418 hasAuthorship W4225139418A5010332288 @default.
- W4225139418 hasAuthorship W4225139418A5012891156 @default.
- W4225139418 hasAuthorship W4225139418A5013097108 @default.
- W4225139418 hasAuthorship W4225139418A5014757042 @default.
- W4225139418 hasAuthorship W4225139418A5017423714 @default.
- W4225139418 hasAuthorship W4225139418A5036760276 @default.
- W4225139418 hasAuthorship W4225139418A5043793593 @default.
- W4225139418 hasAuthorship W4225139418A5056275493 @default.
- W4225139418 hasAuthorship W4225139418A5059386925 @default.
- W4225139418 hasAuthorship W4225139418A5059906345 @default.
- W4225139418 hasAuthorship W4225139418A5061316293 @default.
- W4225139418 hasAuthorship W4225139418A5061978120 @default.
- W4225139418 hasAuthorship W4225139418A5064814823 @default.
- W4225139418 hasAuthorship W4225139418A5066059486 @default.
- W4225139418 hasAuthorship W4225139418A5069533019 @default.
- W4225139418 hasAuthorship W4225139418A5069840184 @default.
- W4225139418 hasAuthorship W4225139418A5074596928 @default.
- W4225139418 hasAuthorship W4225139418A5079708396 @default.
- W4225139418 hasAuthorship W4225139418A5079990486 @default.
- W4225139418 hasAuthorship W4225139418A5083608773 @default.
- W4225139418 hasAuthorship W4225139418A5084283817 @default.
- W4225139418 hasAuthorship W4225139418A5085694830 @default.
- W4225139418 hasBestOaLocation W42251394181 @default.
- W4225139418 hasConcept C126322002 @default.
- W4225139418 hasConcept C156957248 @default.
- W4225139418 hasConcept C159654299 @default.
- W4225139418 hasConcept C203014093 @default.
- W4225139418 hasConcept C22070199 @default.